Patient, Steve Tuck,

a patient representative on behalf of Prostate Cancer UK and Movember, will drive our Patient and Public Involvement (PPI) partnership. Steve is also the current Chair of Oxfordshire Prostate Cancer Support Group. The PPI Sub-committee will also be strongly supported by ecancer, an entity with a track record in modern targeted medical communication to both press and public.


ReIMAGINE Webinar Series

Topic: ReIMAGINE: The game changer in prostate cancer diagnosis and prognosis

Date: September 10th 2020                                                                         Time: 03:00PM











Prostate cancer: Check your risk in 30 seconds


This September ReIMAGINE are supporting Prostate Cancer UK to get men at risk of prostate cancer (men over 50, black men, men with a family history of the disease) to talk to their GP about their risk.


You can help. Take their online risk checker [insert link]





ReIMAGINE is committed to Patient and Public Involvement (PPI) at all stages of research involving cancer populations. PPI means actively working in partnership with patients and members of the public to plan, manage, design and carry out research. This involves informing the decision making process of researchers, which can entail reviewing content,  prioritising outcomes and/or evaluating impact.


The Black, Asian, and minority ethnic (BAME) community are disproportionately under-represented in research. For this reason, we are very keen to ensure that more people from BAME backgrounds engage in research, and therefore we would like to form a PPI Cancer Group exclusively for the BAME community.  Your participation in this special interest group will inform research and ultimately improve cancer outcomes and reduce health inequalities.

Help contribute to research by signing up. For more information please email Saran Green, Patient and Public Involvement Coordinator for ReIMAGINE –


This study is being launched with funding of £4.1m from the Medical Research Council and £1m from Cancer Research UK, as part of the MRC's Stratified Medicine Initiative. 


© 2018 ReIMAGINE